Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2020
Price : $35 *
At a glance
- Drugs XT-150 (Primary)
- Indications Osteoarthritis; Pain
- Focus Adverse reactions
- Sponsors Xalud Therapeutics
- 06 Nov 2019 Status changed from active, no longer recruiting to completed.
- 09 Oct 2019 Planned End Date changed from 1 Sep 2019 to 1 Nov 2019.
- 16 Jan 2019 Planned End Date changed from 1 Aug 2019 to 1 Sep 2019.